TCGA-GM-A3XG-01A-31R-A24H-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 44
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.380
- MYOGENESIS+0.330
- KRAS_SIGNALING_DN+0.280
- OXIDATIVE_PHOSPHORYLATION+0.260
- ESTROGEN_RESPONSE_LATE+0.230
- APICAL_JUNCTION+0.220
- ESTROGEN_RESPONSE_EARLY+0.210
- XENOBIOTIC_METABOLISM+0.210
- P53_PATHWAY+0.200
- FATTY_ACID_METABOLISM+0.190
Top 10 suppressed
- E2F_TARGETS-0.640
- G2M_CHECKPOINT-0.630
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.510
- PROTEIN_SECRETION-0.500
- MITOTIC_SPINDLE-0.480
- MTORC1_SIGNALING-0.410
- INFLAMMATORY_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR29022836 | — | A | 0.904 |
| 2 | TCGA-AR-A5QP-01A-11R-A28M-07 | — | A | 0.890 |
| 3 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.885 |
| 4 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.869 |
| 5 | TCGA-OL-A66K-01A-11R-A29R-07 | — | B | 0.858 |
| 6 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.856 |
| 7 | SJEPD001534_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.853 |
| 8 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.852 |
| 9 | AUR-AEPZ-TTP1-A-1-1-R-A742-41 | — | B | 0.846 |
| 10 | aMVAC.P_003_TURBT_S220 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |